Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Unlike opioids, which bind to µ-opioid receptors within the central nervous system, conolidine modulates alternate molecular targets. A Science Improvements analyze observed that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabili... https://zbigniewn432zur4.blogoxo.com/profile